Pharmacokinetics cytostatic

Sculier, J. P., Coune, A., Brassine, C., Laduron, C., Atassi, G., Ruysschaert, J. M., and Fruhling, H. (1986). Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data, J. Clin. Oncol., 4, 789-797. 

Drug interactions with paclitaxel have been reviewed (52). The most important of these are the pharmacodynamic interactions with other cytostatic drugs, but pharmacokinetic interactions have also been described. 

Lipp HP, Bokemeyer C. Clinical pharmacokinetics of cytostatic drugs efficacy and toxicity (2.2. platinum compounds as anticancer drugs). In Lipp HP, editor. Anticancer drug toxicity prevention, management and clinical pharmacokinetics. New York-Basel Marcel Dekker Inc, 1999 61-81. 

Cellular uptake and inhibition of DNA synthesis S. Kunjmoto et al. J. Antibiot 36, 312 (1983) and cytostatic activity S. Kunimoto et al. ibid. 37, 1697 (1984). Pharmacokinetics and tissue distribution H. Iguchi ei al.. Cancer Chemother. Pharmacol. 15, 132 (1985). Clinical pharmacology A. A. Miller, C. G. Schmidt, Cancer Res. 47, 1461 (1987). Clinical studies in breast cancer G. Mathe et ai.. Biomed. Pharmacother. 40, 376 (1986) in leukemia and malignant lymphoma R. Ohno ef al. Cancer Chemother. Pharmacol 20, 230 (1987). Brief review of early clinical evaluations H. Majima, K. Ohta, Biomed. Pharmacother. 41, 237-243 (1987). 

The pharmacokinetics of intra-arterially applied cytostatics has been studied in detail by Stephens (Stephens 1983). Based on cardiovascular physiology, he described an excellent model to account for the advantage of intra-arterial over intravenous applications. In this model, the intravenously applied dose of a drug should be 100%. If it is assumed that 10% of the dose is distributed in the tumor and the... 

---